Were You Diagnosed With Cutaneous T-Cell Lymphoma After Using Dupixent?
Here’s what recent research reveals about Dupixent’s cancer risks and whether your diagnosis qualifies you for compensation.
Dupixent (dupilumab) is a biologic injection commonly prescribed for conditions like eczema, asthma, and chronic sinus inflammation. While the medication has helped many patients manage severe symptoms, new medical reports have raised concerns about a potential connection between Dupixent and Cutaneous T-Cell Lymphoma (CTCL), a rare but serious form of skin lymphoma that can initially resemble eczema.
As more cases are identified, patients around the country have begun pursuing Dupixent cancer claims, alleging that the drug’s manufacturers failed to adequately warn about the possibility of misdiagnosis, delayed detection, or disease progression after starting the injection.
Slater & Zurz is actively reviewing Dupixent lymphoma cases to help the Ohio community understand whether their medical history, treatment timeline, and pathology findings may meet eligibility criteria for compensation.
On this page, you’ll find:
- Who may qualify for a Dupixent T-Cell Lymphoma lawsuit
- What emerging research shows about Dupixent and CTCL
- Updates on current Dupixent cancer litigation
- What to expect when pursuing a claim through our firm
Am I Eligible to File a Dupixent T-Cell Lymphoma Lawsuit?
To determine whether you qualify for a Dupixent lawsuit, our attorneys start by examining your treatment timeline, diagnosis, and how your symptoms progressed. Use this checklist to understand whether your situation may qualify.
1. You received Dupixent (dupilumab) injections
This includes Dupixent prescribed for:
- Moderate to severe eczema (atopic dermatitis)
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Other off-label inflammatory or allergic conditions
Current Dupixent cancer lawsuits focus primarily on patients who used Dupixent for several months or longer, since extended biologic exposure is central to the concerns raised in current litigation. If you don’t remember exactly when your injections began, dermatology, allergy, or pharmacy records can usually fill in the details.
2. You were diagnosed with one of the following cancers
You may qualify if you were diagnosed with:
- Cutaneous T-Cell Lymphoma (CTCL)
- Mycosis Fungoides
- Sezary Syndrome
- Other T-cell lymphomas confirmed through biopsy
- A lymphoma that was initially misdiagnosed as eczema or dermatitis
3. Your diagnosis occurred during or after Dupixent therapy
CTCL can progress slowly, which means a diagnosis after stopping Dupixent can still be consistent with expected patterns of biologic-related immune dysregulation. You may qualify if your lymphoma was discovered while actively using Dupixent, after months or years of Dupixent treatment, or after symptoms worsened following the start of the medication.
What is Dupixent (dupilumab)?
Unlike standard creams or pills, Dupixent works by calming parts of the immune system that trigger flare-ups, itching, and swelling. It’s given as an injection every two to four weeks, either at home or in a doctor’s office. Many patients describe it as an “allergy shot” or “immune therapy shot,” since it’s designed to reduce the overactive immune response behind long-lasting skin and breathing symptoms.
How Dupixent may be linked to T-Cell Lymphoma
A 2025 systematic review in Dermatitis examined 35 case reports, case series, and retrospective studies involving people treated with dupilumab. The authors found a recurring pattern: in some patients, rashes diagnosed as severe eczema later turned out to be CTCL, with symptoms that worsened or evolved during Dupixent treatment. The review notes two main possibilities: misdiagnosed CTCL from the start, and potential immune changes from Dupixent that could influence how T-cell cancers behave.
Similarly, in 2024, a study in the Journal of the American Academy of Dermatology used a large health-records database to compare atopic dermatitis patients who did and did not receive dupilumab. Patients on Dupixent had about a 4x higher risk of being diagnosed with CTCL than those who never received the drug, with most CTCL diagnoses occurring more than a year after treatment began.
Taken together, these studies don’t conclusively prove that Dupixent causes T-cell lymphoma, but they do support what many Dupixent CTCL lawsuit filings now argue: there is enough evidence of a risk to justify better screening, clearer warnings, and closer follow-up when rashes are atypical or not improving.
FDA safety signal and ongoing review
In March 2025, the FDA publicly listed “Dupixent (dupilumab) – Cutaneous T-cell lymphoma” as a “potential signal of a serious risk” in its quarterly FAERS safety update. In that same notice, the agency stated that it is “evaluating the need for regulatory action.”
For patients considering a Dupixent cancer lawsuit, the FDA’s safety signal matters because it confirms that CTCL after Dupixent isn’t just a handful of isolated anecdotes. Instead, enough CTCL cases have been reported after Dupixent use to trigger a formal safety review, and regulators are now assessing whether the drug’s warning label, prescribing information, or monitoring recommendations need to be updated.
Signs and symptoms of T-cell lymphoma (CTCL) after Dupixent
CTCL often begins subtly, which is why it is frequently mistaken for eczema or dermatitis, which are the very conditions Dupixent is meant to treat. In the early stages, CTCL may appear as red, itchy, or scaly patches that come and go over months or years. Many patients describe these areas as “eczema that never fully clears,” even with steroid creams, biologic drugs, or allergy injections.
As the disease progresses, symptoms can deepen or change. Some individuals develop thickened plaques, darker or more persistent lesions, or rashes that begin spreading to new areas of the body. Others experience patches with sharper borders, changes in skin texture, or lesions that feel different than their long-standing eczema.
More advanced CTCL can cause symptoms beyond the skin, including:
- Swollen lymph nodes, especially in the neck, armpits, or groin
- Persistent itching that does not improve with eczema treatments
- Open sores or ulcerations
- Painful, burning, or tender patches
- Fatigue or unexplained weight loss
- Skin that becomes thin, fragile, or prone to tearing
- In Sezary Syndrome, diffuse redness of the skin, hair loss, or changes in nails
Latest Dupixent Cancer Lawsuit Updates (and What They Mean for Your Case)
Most Dupixent T-cell lymphoma lawsuits filed so far focus on manufacturers’ failure to warn about CTCL risk. Victims argue that Sanofi and Regeneron knew or should have known about a potential increased risk of CTCL and related cancers but did not include clear warnings for patients or prescribers.
They claim that if stronger label warnings or monitoring guidance had been in place, doctors may have ordered a skin biopsy or lymph node work-up sooner, potentially catching T-cell lymphoma earlier and reducing the risk of progression.
These allegations are still being tested in court, and no large global settlement framework has been announced yet. But the combination of published research, FDA monitoring, and increasing case filings is exactly what fuels a growing wave of Dupixent CTCL lawsuit activity. If you’re ready to explore your legal options, contact us at 330-762-0700 or fill out the form below.
What Does Compensation Cover in a Dupixent T-Cell Lymphoma Case?
A diagnosis of CTCL can reshape nearly every part of a person’s life. While every case is evaluated individually, lawsuits involving CTCL and other T-cell lymphomas commonly seek damages for the significant losses these conditions create:
- Medical expenses: This includes biopsies, dermatology visits, oncology care, imaging, phototherapy, radiation, chemotherapy, immunotherapy, stem-cell transplantation, and long-term monitoring.
- Future medical needs: CTCL often requires lifelong management. Compensation may include projected costs for continued treatment, follow-up testing, or progression-related care.
- Lost wages and reduced earning capacity: Many patients face extended time away from work due to treatment schedules, side effects, or worsening symptoms. Severe cases (such as Sezary Syndrome or advanced Mycosis Fungoides) may impact a person’s ability to continue working altogether.
- Pain and suffering: CTCL can cause chronic itching, painful plaques, skin tenderness, widespread redness, and systemic symptoms. Claims may account for physical discomfort, fatigue, and the stress of living with a chronic form of cancer.
- Emotional distress: Delayed diagnosis, misdiagnosis, and the uncertainty of a cancer progression path can lead to anxiety, depression, and trauma, all of which may be considered in a lawsuit.
- Wrongful death damages: In rare but severe cases, CTCL and Sezary Syndrome can become life-threatening. Families may pursue compensation for funeral costs, loss of companionship, and the financial impact of a loved one’s passing.
Because Dupixent litigation is still developing, settlement values vary widely. However, claims involving advanced CTCL, delayed cancer detection, or extensive treatment often qualify for higher compensation due to the long-term impact on health and quality of life.
Don’t Wait to Get Answers.
Learning that a medication meant to help could be connected to a cancer diagnosis is overwhelming, especially when symptoms may have been mistaken for eczema for months or even years. If you were diagnosed with Cutaneous T-Cell Lymphoma, Mycosis Fungoides, or Sezary Syndrome after using Dupixent, you don’t have to navigate the next steps alone.
Our team at Slater & Zurz is here to review your medical history, answer your questions, and explain what a Dupixent lawsuit could mean for you and your family. Whether you’re dealing with ongoing treatment, a recent diagnosis, or uncertainty about how your symptoms evolved, we can help you understand your legal options.
Most importantly, you will never pay upfront. We only receive a fee if we successfully recover compensation on your behalf.
Take the first step by calling us at 330-762-0700 or fill out our form for a free, confidential case evaluation.
Frequently Asked Questions About Dupixent Cancer Lawsuits
- Can Dupixent cause Cutaneous T-Cell Lymphoma (CTCL)?
- Multiple published case reports show that Dupixent may mask early signs of CTCL or delay proper diagnosis, especially in patients whose symptoms closely resemble eczema. Many lawsuits claim that Dupixent allowed T-cell lymphoma to progress unchecked because patients and doctors believed they were treating a severe inflammatory condition instead of cancer.
- What types of cancers are linked to Dupixent lawsuits?
- Most cases involve CTCL, Mycosis Fungoides, Sezary Syndrome, and other T-cell lymphomas that appear in the skin. These cancers often begin with chronic rashes, red patches, plaques, or itching, which are symptoms that are easily confused with eczema.
- What evidence do I need to file a Dupixent lawsuit?
- Common documentation includes: medical records showing Dupixent prescriptions, dermatology notes, biopsies, or pathology reports, a timeline of symptoms before and after starting Dupixent, and CTCL or lymphoma diagnosis details. If you don’t have all of this yet, that’s okay — we can help you understand what’s needed.
- How much does it cost to hire a Dupixent lawyer?
- There is no upfront cost. Slater & Zurz handles these cases on a contingency fee, meaning you pay nothing unless we recover compensation for you.
- What compensation might be available?
- Possible damages include medical expenses, long-term treatment needs, lost income, reduced earning ability, pain and suffering, emotional distress, and (in severe cases) wrongful death damages.
- How long do Dupixent cancer cases take?
- Medication-injury cases often take months or years, depending on how the scientific evidence develops, how many lawsuits are filed, and whether federal courts consolidate cases. Timelines vary widely, but starting early ensures your claim fits within Ohio’s deadlines.
- Is there a statute of limitations in Ohio for filing a Dupixent cancer lawsuit?
- Yes. Ohio has strict time limits for medication-injury claims. The clock generally starts when a patient “knew or should have known” that their diagnosis might be connected to a medication. Contacting an attorney quickly helps protect your right to file.
- Will my doctor be involved in the lawsuit?
- Most lawsuits focus on the drug manufacturer, not the prescribing physician. Your doctor’s records may be needed, but they are not typically sued in this type of claim.
- What if my biopsy or diagnosis is still pending?
- You may still qualify for an early review. Many patients seek legal help while undergoing testing because CTCL evaluation can take time and sometimes requires multiple biopsies.